Platelets level variability during the first year after liver transplantation in the risk prediction model for recipients mortality.


Journal

Annals of hepatology
ISSN: 1665-2681
Titre abrégé: Ann Hepatol
Pays: Mexico
ID NLM: 101155885

Informations de publication

Date de publication:
Historique:
received: 13 01 2020
revised: 03 03 2020
accepted: 05 03 2020
pubmed: 17 4 2020
medline: 22 6 2021
entrez: 17 4 2020
Statut: ppublish

Résumé

Many scoring systems in liver diseases use static values of liver function parameters. These parameters may change significantly in liver transplant (LTx) recipients over time due to various processes. The study was aimed at building a new model for survival prediction after LTx based on variability of selected parameters. The study included 450 LTx recipients who survived a minimum one year after transplantation. We analyzed liver enzymes and hematology parameters static values and their variability during the first year after transplantation. Modeling patients' survival was performed using Cox regression. Various sets of parameters (both static and variability and trends values) were tested to predict survival in our study group. Models' performance was measured using the concordance index. The single predictors of the patients survival were the static values of AST with C-index 0.706 (0.5883-0.7494), ALT 0.6102 (0.4843-0.6857) and bilirubin 0.6224 (0.5537-0.6695). High prediction scores were observed for variability in creatinine 0.6023 (0.5409-0.6451), PLT 0.6350 (0.5491-0.7043), RBC 0.5689 (0.5065-0.6213) and WBC 0.6506 (0.5095-0.7124). Our best-fitted and proposed model for patients survival after LTx has C-index 0.8273 (IQR 0.7767-0.8649). The model uses the following indicators for mortality prediction: the static value of AST, variability measure of PLT and trend measures of WBC and PLT. Adding variability and trend measures increases predictive accuracy in modeling patients survival after LTx. We propose a high-accuracy survival model in which variability and trend of PLT measures in the first year after transplantation are strong predictors of long-term mortality.

Identifiants

pubmed: 32295734
pii: S1665-2681(20)30026-0
doi: 10.1016/j.aohep.2020.03.004
pii:
doi:

Substances chimiques

Creatinine AYI8EX34EU
Aspartate Aminotransferases EC 2.6.1.1
Alanine Transaminase EC 2.6.1.2
Bilirubin RFM9X3LJ49

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-421

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Wojciech Jarmulski (W)

Polish-Japanese Academy of Information Technology, 86 Koszykowa St, Warsaw, Poland. Electronic address: w.jarmulski@gmail.com.

Alicja Wieczorkowska (A)

Polish-Japanese Academy of Information Technology, 86 Koszykowa St, Warsaw, Poland. Electronic address: alicja@poljap.edu.pl.

Mariusz Trzaska (M)

Polish-Japanese Academy of Information Technology, 86 Koszykowa St, Warsaw, Poland. Electronic address: mtrzaska@mtrzaska.com.

Ewa Hryniewiecka (E)

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, 59 Nowogrodzka St, Warsaw, Poland. Electronic address: elhryniewiecka@gmail.com.

Leszek Pączek (L)

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, 59 Nowogrodzka St, Warsaw, Poland; Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 5A Pawinskiego St, Warsaw, Poland. Electronic address: leszek.paczek@wum.edu.pl.

Michał Ciszek (M)

Department of Immunology, Transplant Medicine and Internal Diseases, Medical University of Warsaw, 59 Nowogrodzka St, Warsaw, Poland. Electronic address: m.ciszek@wum.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH